Comprehensive AAV Gene Therapy CMC Services

SMAT Consultants provides AAV gene therapy CMC strategy, execution, and senior leadership for drug developers, manufacturers and CDMOs, as well as investors and strategic partners. Engagements range from focused projects and advisory retainers to fractional Head of CMC or interim CTO leadership.

Drug developers: vector design and manufacturability, process and analytical development, stability, CDMO selection and oversight, technology transfer, comparability, clinical supply chain, and regulatory CMC from IND through BLA.

Manufacturers and CDMOs: process and analytical optimization, technology transfer, GMP readiness, facility evaluation from an operational perspective, cross-contamination risk mitigation, and manufacturing investigations and troubleshooting.

Investors and strategic partners: independent technical due diligence, COGS and manufacturing risk assessment, CMC planning, and portfolio company support.

Drawing on 30+ years of AAV CMC experience, from hands-on execution to CTO-level leadership, SMAT Consultants combines scientific depth with practical business judgment to help clients manage technical risk, timelines, budgets, and regulatory requirements across the AAV development lifecycle.

Vector Design & Optimization
Plasmid Design & Manufacturing
Cell Line Development
Supply Chain & Logistics
Drug Substance
Drug Product
Analytical Development
Facility & Equipment Strategy
Vendor Management & Tech Transfer
Regulatory & Quality
CMC Strategy & Cost Optimization
CMC Due Diligence
Get Started

Vector Design & Optimization

Vector design decisions drive both therapeutic outcomes and manufacturing economics — performance and manufacturability are often compatible, but certain design choices create trade-offs that need to be anticipated and balanced deliberately. We support drug developers, manufacturers, and CDMOs across vector design and manufacturability assessment for AAV programs.

Vector Design Services:

  • Capsid selection and serotype optimization for target tissue

  • Genome size and ITR configuration assessment (ssAAV and scAAV packaging fit, ITR truncation options)

  • Terminal resolution site (TRS) modification design for scAAV

  • D-sequence identification and characterization

  • Promoter selection (including tissue-specific promoters) and expression cassette optimization

  • Regulatory element selection and positioning strategy (polyA signals, introns, WPRE, microRNA target sites, etc.)

  • Codon optimization strategies

  • CpG content optimization

  • Payload capacity assessment and optimization

  • Transgene stability evaluation

  • Regulatory strategy for novel vector design modifications and comparability assessments

Manufacturability Assessment:

  • Plasmid design for optimal AAV yields

  • Plasmid system architecture selection (dual vs. triple plasmid systems for transient transfection)

  • Helper system evaluation (traditional and minimal helper approaches)

  • Production efficiency assessment of capsid variants

  • Empty capsid propensity assessment of different constructs

  • Manufacturability assessment of difficult-to-package payloads

  • Scale-up planning and risk assessment

Integrated Vector Design & Optimization:

Vector design decisions affect therapeutic performance and manufacturing scalability simultaneously. We help anticipate how capsid, genome configuration, payload, and regulatory element choices affect yield, scale-up, and program economics down the line.

Discuss Vector Design
Top of Page

Plasmid Design & Manufacturing

Plasmid DNA design and quality directly affect AAV yield, vector integrity, and regulatory acceptability. We support drug developers, manufacturers, and CDMOs across plasmid design, banking, GMP manufacturing strategy, and quality analytics for AAV programs.

Plasmid Design:

  • Plasmid backbone optimization (size reduction, removal of unnecessary sequences)

  • Antibiotic resistance marker selection and antibiotic-free selection system evaluation

  • Origin of replication selection and copy number optimization

  • Plasmid architecture optimization for ITR stability during bacterial production

  • Plasmid design strategies for multimer and dimer prevention

  • Replication-competent AAV (rcAAV) risk mitigation through plasmid redesign

  • Plasmid stability assessment and improvement

  • Vendor coordination for plasmid production implementation

  • Regulatory strategy for plasmid system and design choices

Plasmid Banking:

  • Bacterial cell bank generation strategy and coordination

  • Working bank qualification strategy and protocol design

  • Stability and quality testing program design

  • Regulatory documentation strategy and preparation

GMP Manufacturing:

  • Bacterial strain selection (Stbl2, SURE, DH10B, and other strains for ITR stability and yield optimization)

  • Fermentation process optimization and technology evaluation

  • Purification method review and improvement recommendations

  • Endotoxin and RNA removal strategy optimization

  • Regulatory-grade documentation guidance

Plasmid Quality & Analytics:

  • Identity testing strategy (restriction mapping, sequencing, NGS-based identity verification)

  • Purity assessment protocols (endotoxin, RNA, chromosomal DNA, residual host cell protein)

  • Structural integrity analysis (supercoiling form analysis via CGE, AGE)

  • Stability testing program design

  • Release testing specification development

Integrated Plasmid Strategy:

Plasmid manufacturing decisions made in isolation often surface as AAV manufacturing problems months later. We help anticipate how plasmid design and quality choices affect downstream AAV yield, vector integrity, and regulatory submissions — bringing integrated plasmid expertise grounded in AAV manufacturing experience.

Discuss Plasmids
Top of Page

Cell Line Strategy & Development

Cell line decisions drive AAV yield, batch consistency, and scale-up risk. We support drug developers, manufacturers, and CDMOs across cell line development, banking, advanced cell line strategies, and platform selection — for in-house programs and external manufacturing.

Cell Line Development & Optimization:

  • Cell line adaptation to suspension growth and serum-free conditions

  • Clonal selection and screening protocols

  • High-throughput clonal screening for productivity selection

  • Cell line characterization and genetic stability

  • Cell line productivity benchmarking across serotypes

Cell Banking & Documentation:

  • Master cell bank (MCB) generation and qualification

  • Working cell bank (WCB) development

  • Cell bank stability monitoring program design

  • Regulatory documentation strategy and preparation for cell banks

Advanced Cell Line Strategies:

  • Stable producer cell line generation (integrated rep/cap and vector genome; helper functions integrated or supplied by infection)

  • Packaging cell line development (integrated rep/cap)

  • Multi-plasmid stable integration strategies

  • Cell line licensing and freedom-to-operate assessment

Platform Capabilities:

  • Platform selection guidance based on program requirements

  • HEK293-based systems

  • SF9/baculovirus platforms

  • Alternative mammalian cell lines

  • Suspension vs. adherent systems

  • Platform-specific regulatory strategy

Integrated Cell Line Strategy:

Cell line decisions cascade across program phases — early development choices shape banking strategy, banking decisions affect regulatory submissions, and platform choices constrain advanced cell line options. We design integrated cell line strategies — across development, banking, advanced approaches, and platform selection — that match phase-appropriate program needs.

Discuss Cell Line Development
Top of Page

Drug Substance Process Development & Manufacturing

Upstream Process Development & Manufacturing

Upstream process decisions drive AAV titer, vector quality, and batch-to-batch consistency. We support drug developers, manufacturers, and CDMOs across the upstream workflow — from transfection through cell culture and productivity optimization to manufacturing scale-up.

Production Platform Selection:

  • Transient transfection systems (HEK293)

  • Baculovirus/SF9 systems

  • Stable producer cell lines

  • HSV helper systems

  • Platform comparison for your specific vector

Transfection Optimization:

  • Method comparison (PEI, calcium phosphate, lipid-based)

  • Transfection reagent screening and optimization

  • DNA-reagent complex formation protocol design

  • Plasmid ratio optimization

  • Timing and feeding strategy development

  • Scale-up planning from bench to manufacturing

Cell Culture Optimization:

  • Cell density assessment at transfection

  • Media selection and optimization

  • Feed strategy selection (batch, fed-batch, perfusion)

  • Harvest timing recommendations based on productivity and quality

  • Viral vector aggregation prevention through process design

Productivity Enhancement:

  • Yield optimization strategies

  • Process parameter screening (DoE approaches)

  • Critical process parameter (CPP) identification

  • Process monitoring and control framework

  • Media and raw material sourcing planning

Scale-Up Support:

  • Bench-to-commercial scale-up planning (small scale through pilot to commercial)

  • Bioreactor selection and specification (Ambr15/Ambr250 development scale through stirred tank manufacturing scale)

  • Process performance characterization across scales

  • CPP and CQA verification at scale

  • Tech transfer support coordination with manufacturing site

Downstream Process Development & Manufacturing

Purification strategy decisions shape AAV product quality, yield economics, and regulatory submission strength. We work with drug developers, manufacturers, and CDMOs across the purification train — from clarification through capsid separation to final polishing.

Clarification:

  • Depth filtration optimization

  • Flocculation pretreatment design

  • Filter sizing and selection

  • Fouling mitigation strategies

  • Benzonase treatment recommendations

  • Centrifugation alternative assessment

Primary Purification:

  • Affinity chromatography selection and optimization (POROS CaptureSelect, AVB Sepharose, AVIPURE)

  • Heparin chromatography assessment and optimization

  • Monolith chromatography evaluation

  • Platform method development for multiple serotypes

Empty/Partial/Full Capsid Separation:

  • Ion exchange chromatography selection (Capto Q, Capto Q ImpRes, other AEX resins)

  • Ion exchange gradient optimization

  • Ultracentrifugation assessment (CsCl or iodixanol)

  • Combination strategies for challenging serotypes or high purity requirements

  • Analytical method development for monitoring (AUC, AEX-HPLC)

Polishing & Concentration:

  • TFF/ultrafiltration design

  • Size exclusion chromatography step design

  • Buffer exchange evaluation

  • Concentration factor optimization

  • Aggregate removal strategy and method development

Viral Clearance:

  • Evaluation of clearance by individual purification steps

  • Nanofiltration evaluation

  • Clearance study design

Integrated Drug Substance Process Development & Manufacturing:

Upstream and downstream decisions are linked — upstream process choices affect downstream impurity profiles, productivity drives downstream throughput, and harvest conditions shape purification challenges. We help anticipate and manage these interactions across the full drug substance workflow, optimizing both halves of the process together rather than sequentially.

Discuss Drug Substance
Top of Page

Drug Product Process Development & Manufacturing

Drug product decisions drive AAV stability, sterility assurance, and regulatory submission strength. We support drug developers, manufacturers, and CDMOs across the drug product workflow — from formulation development and container/closure compatibility through fill-finish operations.

Formulation Development:

  • Excipient screening and selection

  • Buffer system selection and optimization

  • pH and ionic strength optimization

  • Surfactant evaluation (Poloxamer P188, polysorbate 20/80)

  • Cryoprotectant screening

  • Stability enhancement strategies

  • Freeze-thaw study design

  • Long-term and accelerated stability program design

  • Stability protocol and sampling-plan development

  • Osmolality and tonicity adjustments for administration route

Container/Closure & Device Compatibility:

  • Vial material evaluation (glass types, plastic)

  • Stopper and seal compatibility evaluation

  • Extractables and leachables study design

  • Storage container optimization

  • Syringe compatibility assessment

  • Administration device compatibility assessment

Fill-Finish Process Development:

  • Sterile filtration strategy design

  • Disinfection strategy development (routine and post-spill protocols for aseptic operations)

  • Aseptic filling process development

  • Fill volume and overfill optimization

  • In-process and release testing strategy

  • Visual inspection criteria development

  • Container closure integrity testing approach

Integrated Drug Product Process Development & Manufacturing:

Drug product decisions cascade across formulation, container/closure, and fill-finish — formulation must accommodate vector aggregation tendencies, drug substance titer determines fill volume which can constrain administration feasibility, and aggregation behavior affects sterile filtration recovery and final yield. We help design these decisions together to optimize stability, sterility assurance, and commercial supply continuity.

Discuss Drug Product
Top of Page

Clinical Supply Chain & International AAV Logistics

Clinical supply is where otherwise sound programs can lose material and time. International AAV shipments depend on lane selection, shipper configuration, customs and import/export requirements, as well as a cold chain that has to remain within qualified conditions throughout the journey. We support drug developers, manufacturers, and CDMOs across the supply workflow, from shipping strategy and cold chain qualification through provider selection to excursion assessment and material disposition support.

Supply Network Design & Operating Procedures:

  • Shipping lane assessment and route selection

  • Origin-to-site supply mapping for multi-country trials

  • Depot strategy, including multiple regional depots for risk mitigation and proximity to clinical sites

  • Transit time, risk, and contingency routing analysis

  • Procedure development for handoff steps not covered by existing manufacturer, courier, depot, or site procedures

  • Implementation and training support for those procedures

  • Ongoing oversight and verification that critical transfer steps are executed as written

Cold Chain Design & Qualification:

  • Temperature regime selection, including ultra-low temperature, dry ice, and liquid nitrogen vapor

  • Packaging strategy assessment for drug substance and drug product

  • Shipper selection and transport simulation study design

  • Shipping qualification and validation study planning

  • Temperature monitoring and data logger strategy

  • Allowable excursion limits defined against available stability data

  • Temperature excursion study design

Logistics Provider Selection & Oversight:

  • Provider evaluation against demonstrated AAV and frozen biologic capability

  • Assessment of provider capability in customs clearance, import permits, and in-transit intervention including dry ice replenishment

  • Depot and storage site qualification support

  • Scope definition, service agreements, and performance metrics

  • Chain-of-custody and cross-border handoff definition

  • Provider oversight, escalation paths, and issue management

  • Audit and qualification support

Risk Management & Material Disposition:

  • Risk assessment for single-source material and long transit lanes

  • Contingency planning for lane disruption and shipment loss

  • Global distribution planning across clinical sites

  • Temperature excursion investigation and technical assessment

  • Material disposition support, with Quality retaining formal release authority

  • Inventory and resupply planning for clinical sites

  • Deviation documentation and regulatory reporting support

Integrated Clinical Supply Chain & International AAV Logistics:

Supply chain decisions connect directly to formulation, container closure, and stability. The temperature regime a product can tolerate determines which shipping conditions and lanes are available, shipper configuration affects excursion risk, and the available stability data determine which deviations can be supported technically.

The highest-risk steps are often the handoffs between manufacturer, courier, depot, and clinical site, where responsibility passes from one organization to another and each party’s procedures stop short of the next. Logistics providers should therefore be evaluated not only on scale or general pharmaceutical distribution capability, but on demonstrated experience with frozen gene therapy material, the required shipping conditions, and the specific international lanes a program needs.

We bring these elements together so that material arrives at clinical sites intact, on schedule, and with the documentation required for release.

Discuss Supply Chain
Top of Page

Analytical Development & Characterization

Vector Characterization Methods

We develop, qualify, and evaluate vector characterization methods — titer, empty/full ratio, capsid protein, and vector purity — for drug developers, manufacturers, and CDMOs.

Vector Quantification Methods:

  • Genome titer assay development by ddPCR

  • Capsid ELISA establishment for total capsid concentration

  • Optical density (A260/A280) method qualification

  • Method comparison and correlation studies

Empty/Full Capsid Ratio:

  • Method comparison and selection (AUC, AEX-HPLC, CDMS, TEM)

  • Method development and qualification according to program stage

  • Cross-method correlation studies

Capsid Protein Analysis:

  • VP1:VP2:VP3 ratio characteri­zation by cWB or LC-MS

  • Capsid protein identity confirmation by cWB or LC-MS/MS

  • Post-translational modification characterization by LC-MS

Vector Purity Analysis:

  • Aggregate analysis and characterization (SEC-HPLC, DLS, AUC)

  • Sub-visible particle analysis (HIAC light obscuration, MFI; USP <788>, EP 2.9.19)

  • Visible particle inspection method qualification (USP <790>, EP 2.9.20)

  • CE-SDS analysis for capsid protein purity and integrity

Potency & Infectivity Assays


We establish, qualify, and evaluate potency and infectivity assays for drug developers, manufacturers, and CDMOs — including phase-appropriate strategy and regulatory alignment.

Potency Assay Development:

  • Cell-based potency assay development by in vitro transduction

  • Quantitative potency assay establishment by RT-qPCR-based transgene expression

  • Functional protein assay design for relevant therapeutic targets

  • Reporter gene system selection and method qualification

  • Dose-response curve generation and analysis

Infectivity Assessment:

  • Infectious titer determination by TCID50

  • Physical-to-infectious titer correlation studies (full-to-infectious ratio)

  • Empty capsid impact assessment on infectivity measurements

Method Validation:

  • Method validation strategy and protocols per ICH Q2(R2) and Q14 (specificity, linearity, accuracy, precision, range, robustness)

  • Stability-indicating method development and qualification

  • Method transfer to CROs and other testing partners

Regulatory Strategy:

  • Regulatory alignment strategy for potency and infectivity methods (FDA, EMA expectations)

  • Phase-appropriate potency assay strategy (early development through commercial)

Impurity & Safety Testing Strategy

We design, qualify, and evaluate impurity, safety, and advanced characterization testing strategies for drug developers, manufacturers, and CDMOs across program development.

Process-Related Impurities:

  • Plasmid and host cell DNA quantification by qPCR

  • Residual transfection reagent detection (PEI, calcium phosphate)

  • Residual serum component analysis (when applicable)

  • Residual enzyme assessment (Benzonase and other enzymes)

Safety Testing:

  • Sterility testing design (USP <71>, EP 2.6.1)

  • Endotoxin method selection (LAL or recombinant Factor C; USP <85>, EP 2.6.14)

  • Mycoplasma testing strategy (USP <63>, EP 2.6.7)

  • Adventitious agents testing approaches

  • Replication-competent AAV (rcAAV) detection

  • Residual helper virus assessment (when applicable)

Advanced Characterization:

  • Genome integrity analysis by NGS

  • ssAAV vs. scAAV genome conformation determination

  • Packaged DNA characterization

  • ITR integrity assessment

  • Genome truncation and deletion analysis by multiplex ddPCR

  • Critical quality attribute (CQA) identification and testing strategy

Integrated Analytical Strategy:

Analytical methods and technologies should be selected based on program stage, product attributes, and intended use, and must evolve as the program advances. Characterization sufficient for early development needs to mature for IND/CTA, undergo full validation for BLA/MAA, and stay aligned with regulatory expectations across submissions. We help design phase-appropriate analytical programs that scale from early characterization through commercial release.

Discuss Analytics
Top of Page

Facility & Equipment Strategy

We support manufacturers, CDMOs, and drug developers establishing in-house GMP capabilities with facility evaluation and design input from an operational perspective, including process and laboratory workflow, equipment selection, utility requirements, contamination control, and AAV-specific considerations.

Facility Layout & Operational Design Input

  • Manufacturing suite layout assessment and design input for AAV workflows
  • GMP laboratory layout planning for QC, release, stability, and in-process testing
  • Cleanroom classification strategy (production and fill-finish operations)
  • Equipment placement optimization for process efficiency and GMP compliance
  • Personnel and material flow assessment and design input (dirty/clean transitions, gowning areas)
  • Sample flow and logistics planning within GMP laboratories
  • Differential pressure cascade requirements and design review
  • Contamination control strategy and cross-contamination prevention requirements
  • Biosafety cabinet and isolator placement evaluation
  • Access control and airlock requirements
  • Method transfer and tech transfer readiness assessment for facility planning

Equipment Selection & Strategy

  • Bioreactor specification and selection

  • Filtration equipment evaluation

  • Chromatography systems specification (process-scale)

  • TFF/UF systems selection

  • Automated liquid handling configuration

  • Analytical instrumentation qualification

  • Fill-finish equipment selection (semi-automated BSC/isolator vs. fully automated)

  • Vendor evaluation and comparison

  • Capital equipment prioritization

  • Cost-effective alternatives and value engineering

  • Lease vs. purchase analysis

  • Shared resource strategies

  • Equipment utilization planning

Utility Requirements

  • Water for injection (WFI) systems

  • Cooling water systems and capacity planning

  • Clean steam

  • Clean process gases (point-of-use filtration and quality)

  • Gas supply systems (nitrogen, CO2, O2, compressed air)

  • HVAC and environmental controls

  • Power requirements assessment and electrical distribution

  • Monitoring and alarm systems

  • Emergency backup and redundancy systems

  • Waste management systems

  • Data infrastructure (LIMS, network connectivity)

Operations & Logistics

  • Staffing requirements and personnel planning

  • Cold storage and sample management strategy

  • Chemical storage and handling planning

  • Emergency procedures development

AAV-Specific Considerations

AAV manufacturing introduces specialized facility and operational requirements beyond standard biologics — addressing contamination control for viral vectors, material compatibility with vector-specific disinfection agents, and equipment sizing across the clinical-to-commercial AAV scale range.

  • Material compatibility assessment for oxidizing disinfection agents

  • Contamination control strategy for viral vector production

  • Scale-appropriate equipment sizing strategy

Integrated Facility & Equipment Strategy:

Effective GMP facility planning requires integration of manufacturing processes, equipment strategy, utilities, and AAV-specific considerations from the start. We bring this operational perspective to GMP capability building or expansion, and apply the same expertise to process development and analytical laboratory planning, scaling appropriately to R&D requirements without overdesigning.

Discuss Facility & Equipment
Top of Page

Vendor Management & Tech Transfer

CDMO Selection & Management

CDMO selection and oversight decisions shape program timelines, manufacturing quality, and commercial readiness. We support drug developers in finding, evaluating, selecting, and managing the right manufacturing partner.

CDMO Selection:

  • Capability assessment across multiple CDMOs

  • Track record and references verification

  • Technology platform alignment review

  • Site visit planning and observation

  • Technical audits (process, manufacturing, equipment)

  • Quality audit oversight and review

  • Quality system evaluation

  • Capacity and timeline evaluation

  • Cost comparison and negotiation support

Selection Criteria:

  • AAV manufacturing experience and track record evaluation

  • Serotype-specific expertise vetting

  • Scale capability screening (clinical to commercial)

  • Analytical capabilities assessment

  • Regulatory compliance history review

  • Financial stability and reputation review

  • Geographic location analysis

Contract Negotiation Support:

  • Technical scope definition

  • Technology transfer responsibilities definition

  • Quality agreement terms review and gap assessment

  • Intellectual property provisions review and coordination with IP counsel

  • Cost structure and payment terms analysis

  • Timeline commitment evaluation and risk assessment

Ongoing CDMO Oversight Support:

  • Project oversight and communication

  • Performance metrics tracking

  • Quality review and trending

  • Change control coordination

  • Technical problem solving

  • Stakeholder reporting and communication management

Technology Transfer


Technology transfer success depends on systematic planning, execution, and verification. We support drug developers, manufacturers, and CDMOs through process and analytical method transfers — from strategy through comparability verification.

Tech Transfer Strategy:

  • Critical parameter identification

  • Acceptance criteria definition

  • Risk assessment

  • Equipment difference management and adaptation

  • Raw material and reagent qualification strategy

  • Transfer protocol review and strategy

  • Timeline and resource planning

Transfer Implementation Guidance:

  • Knowledge transfer session facilitation

  • Training facilitation and qualification support

  • Manufacturing demonstration run support and observation

  • Troubleshooting guidance and optimization strategies

  • Process performance gap resolution between sites

  • Documentation review

Analytical Method Transfer:

  • Method transfer protocol review and strategy

  • Side-by-side testing design and oversight

  • Analytical method variability investigation and resolution

  • Method qualification oversight at receiving site

  • Specification alignment review

  • Ongoing method support

Comparability Studies:

  • Risk-based comparability strategy

  • Comparability protocol design

  • Testing strategy development

  • Data analysis and interpretation

  • Regulatory documentation strategy and review

CRO/Testing Laboratory Coordination

External testing reliability depends on careful CRO selec­tion, method transfer, and on­going coordination. We support drug developers, manu­facturers, and CDMOs through testing strategy, CRO selection, method transfer, sample management, and multi-site coordination.

Testing Strategy:

  • Centralized vs. distributed testing strategy

  • Phase-appropriate testing strategy

  • CRO capabilities assessment

  • Method transfer planning

  • Cost optimization

  • Sample logistics and cold chain strategy

CRO Selection:

  • Analytical capability evaluation

  • GMP compliance assessment

  • Quality system review

  • Turnaround time and capacity evaluation

  • Cost comparison

Method Transfer to CROs:

  • Transfer protocol review and strategy

  • Method qualification oversight

  • Specification alignment review

  • Reference standard distribution and management

  • Ongoing performance monitoring

Sample Management:

  • Shipping and cold chain validation

  • Sample stability strategy

  • Chain of custody management

  • Result reconciliation

Multi-Site Coordination:

  • Quality agreement management

  • Centralized data review

  • Inter-site specifications alignment and harmonization

  • Cross-site comparison analysis

  • OOS investigation coordination

Integrated Vendor Management & Tech Transfer:

Vendor selection, tech transfer planning, CRO coordination, and multi-region supply chain decisions accumulate risk across the development lifecycle — affecting timelines, manufacturing reliability, and clinical supply continuity. We help coordinate this work across internal teams, CDMOs, testing laboratories, and other external partners, with vendor recommendations based on independent assessment of technical fit and program needs, not referral relationships or commissions.

Discuss Vendors & Tech Transfer
Top of Page

Regulatory & Quality Strategy

CMC Regulatory Support

CMC regulatory decisions shape submission timelines, agency feedback, and the likelihood of a smooth regulatory review. We support drug developers, manufacturers, and CDMOs across IND/CTA and BLA/MAA submissions — from documentation strategy through agency interactions.

IND/CTA Submission Support:

  • Drug substance manufacturing section

  • Drug product manufacturing and controls

  • Materials and reagents control documentation

  • Analytical methods and validation summary

  • Stability data presentation and program planning

  • Container closure system documentation

  • Manufacturing facility information

  • Phase-appropriate CMC documentation strategy for clinical trial materials

  • Quality control testing program and specifications

BLA/MAA Strategy & Oversight:

  • Expanded manufacturing description strategy and review

  • Process validation strategy and documentation review

  • Commercial manufacturing readiness strategy

  • Analytical validation summary strategy and review

  • Stability commitment fulfillment strategy

  • Comparability protocol design and study execution support

Regulatory Strategy:

  • Phase-appropriate development planning

  • Risk-based testing and control strategy

  • Specification setting and justification

  • Stability testing program design

  • Prior knowledge and platform technology documentation strategy

  • Reference standard strategy and qualification

  • Comparability strategy across process changes (ICH Q5E)

  • Bridging study design for analytical method changes (ICH Q2(R2)/Q14)

FDA/EMA Interactions:

  • Pre-IND meeting preparation support

  • Type B and C meeting support

  • Response to regulatory queries and information requests

  • CMC deficiency response

  • Manufacturing change notification authoring

Quality Systems & Compliance

Quality systems decisions affect product consistency, GMP compliance maturity, and regulatory inspection readiness. We support drug developers, manufacturers, and CDMOs across CMC technical review, quality strategy, gap assessment, audits, and compliance readiness.

CMC Technical Support

  • CMC technical review support for batch records, investigations, and deviation assessments

  • CMC subject matter expert support for regulatory meetings and submissions

  • CMC technical assessment of manufacturing changes and comparability evaluations

GMP Strategy & Framework Review:

  • Manufacturing quality systems strategy and review

  • Batch record template review and gap assessment

  • Deviation management procedure review and strategy

  • CAPA (Corrective and Preventive Action) system strategy and review

  • Change control process strategy and review

Quality Control:

  • Release testing strategy

  • In-process testing program design

  • Stability testing protocol development

  • Out-of-specification (OOS) investigation support

  • Trending and continuous monitoring strategy

Quality Assurance:

  • Quality agreement review and gap assessment (with CDMOs, CROs)

  • Vendor qualification program strategy and review

  • Audit program design and CMC technical support for vendor qualification audits

  • Document control system strategy and review

GMP Compliance & Audit Support:

  • CDMO GMP audit with facility, drawing, and risk review

  • Phase-appropriate GMP compliance audit (clinical-stage programs)

  • Quality system maturity assessment

  • Topic-specific GMP gap analysis (deviation management, comparability, manufacturing quality)

  • Regulatory filing quality review

  • FDA facility readiness evaluation

Contamination & Environmental Control:

  • Cleaning validation strategy and review

  • Cross-contamination risk assessment

  • Environmental monitoring program strategy

Integrated Regulatory & Quality Strategy:

Effective CMC regulatory work depends on robust quality systems, and effective quality systems require regulatory awareness. We help design integrated strategies — across CMC documentation, quality oversight, and GMP compliance — that match phase-appropriate expectations and support successful submissions.

Discuss Regulatory & Quality
Top of Page

CMC Strategic Planning & Cost Optimization

Strategic CMC decisions shape program economics, regulatory pathway, and time-to-market. We support drug developers across CMC strategy, fractional leadership, cost optimization, and fundraising support — for preclinical-stage programs through commercial readiness.

Fractional CMC Leadership & Interim CTO:

  • Fractional Head of CMC for preclinical and clinical-stage programs

  • Interim CTO leadership during transitions, organizational gaps, or periods of rapid growth

  • Company-wide CMC strategy and budget oversight

  • Cross-functional CMC team leadership (PD, manufacturing, QC, QA, regulatory)

  • Board-level CMC reporting and presentation development

  • Crisis management and turnaround support

  • Hiring and team-building support for CMC organizations

CMC Strategy & Program Planning:

  • CMC roadmap development from preclinical to commercial

  • Phase-appropriate CMC strategy planning

  • Critical-path analysis for CMC milestones

  • Manufacturing strategy (in-house vs. outsource decision support)

  • Regulatory pathway integration and CMC strategy alignment

  • Risk-based CMC prioritization across program portfolio

  • Go/no-go decision support for CMC milestones

  • Stakeholder reporting framework development (board, investors, partners)

Cost Optimization & Process Economics:

  • Process economics modeling (cost per batch, cost per dose)

  • COGS modeling and projections across program phases

  • CDMO cost benchmarking across multiple vendors

  • Unit operation cost analysis (upstream, downstream, fill-finish)

  • Sensitivity analysis (yield, purity, titer impacts on cost)

  • Manufacturing yield optimization for cost reduction

  • Capital vs. operating expense trade-off analysis

  • Technology selection for cost-effective production

  • Scale-up cost planning and capital requirements

Fundraising & Investment Support:

  • Manufacturing projections and CMC narrative development for Series A/B fundraising

  • CMC content development and risk assessment for investor presentations

  • Cost projection support for commercial planning and pricing

  • Pre-partnering capability disclosure and CMC due diligence preparation

  • CMC section review for pitch decks and confidential information memoranda (CIMs)

  • Manufacturing risk assessment for investor and partner audiences

  • CMC narrative alignment with clinical and regulatory strategy

Integrated CMC Strategy & Cost Optimization:

Strategic CMC decisions cascade across the program lifecycle — early choices shape clinical timelines, manufacturing decisions affect commercial economics, and CMC team capacity determines execution velocity. We help integrate strategy, leadership, cost, and fundraising support — anchoring every decision to phase-appropriate program needs.

Discuss CMC Strategy
Top of Page

CMC Due Diligence

CMC issues identified late cost more than they should — failed comparability, scale-up surprises, oversized vectors, and regulatory pushback affect valuation, timelines, and program viability. We support investors and strategic partners across CMC due diligence and post-investment portfolio support — from preclinical through commercial stage.

Technology & Platform Assessment:

  • AAV technology platform evaluation (capsid, production system, purification)

  • Vector design and engineering review

  • Vector manufacturability and potency risk assessment

  • Cell line and production system analysis

  • Manufacturing approach assessment (in-house vs. CDMO model)

  • Technology differentiation assessment vs. industry standards

  • Platform scalability evaluation

  • Process maturity review against program stage

Manufacturing & Operational Readiness:

  • Process development capability assessment

  • Manufacturing site readiness and inspection history review

  • CDMO relationship and risk assessment

  • Scale-up readiness assessment (clinical to commercial)

  • Comparability strategy evaluation for process changes

  • Long-term supply continuity evaluation

  • Program timeline review and milestone feasibility assessment

  • CMC organizational capability and team assessment


Regulatory & Quality Readiness:

  • CMC regulatory pathway strategy evaluation (preclinical onward)

  • Phase-appropriate regulatory and quality maturity assessment

  • IND/CTA quality and submission status review (when applicable)

  • BLA/MAA timeline projection analysis

  • GMP compliance and quality system assessment (when applicable)

  • Inspection readiness review for pre-approval (strategic assessment)

  • Analytical method portfolio review (available, planned, phase-appropriate, validation status)

  • CMC regulatory risk factor identification

Cost Economics & Investment Implications:

  • COGS modeling at current scale

  • Commercial-scale COGS projections

  • Industry benchmark comparison

  • Cost reduction opportunity assessment

  • Capital requirements for scale-up evaluation

  • Assessment of CMC timeline implications for valuation

  • CMC considerations affecting investment timing

Risk Assessment & Strategic Recommendations:

  • CMC risk matrix development with prioritization

  • Mitigation strategy recommendations

  • Stage-appropriate risk weighting (preclinical, clinical, commercial)

  • Site visit planning, observation, and reporting

  • Executive summary and board-level reporting

  • Post-investment portfolio improvement planning

  • Follow-up consultation and ongoing advisory support

Post-Investment & Portfolio Support:

  • Selective board, board observer, or SAB participation where appropriate

  • CMC advisory committee contribution for ongoing strategic input

  • Cross-portfolio CMC benchmarking and best-practice sharing

  • Periodic CMC briefings for investment team education

  • Follow-on round CMC due diligence (Series, IPO, M&A)

  • Industry trend and regulatory landscape monitoring for portfolio decisions

Integrated CMC Due Diligence:

CMC issues compound across the program lifecycle — undetected preclinical risks (oversized vectors, suboptimal cell lines, manufacturing-incompatible designs) become expensive clinical-stage problems and commercialization risk, threatening valuations, timelines, and program viability. We help integrate due diligence findings and post-investment portfolio support into actionable insights — anchored in independent assessment of program-specific risks and opportunities.

Discuss Due Diligence
Top of Page

Ready to Discuss Your AAV Program?

Whether you are designing a vector, advancing CMC strategy and execution, optimizing a manufacturing process, building manufacturing and analytical capabilities, selecting a CDMO, or conducting technical due diligence, our services span the full AAV gene therapy CMC lifecycle — with deep expertise in each specific area, informed by direct experience across related domains.

Each engagement combines focused depth in your specific need with integrated insight across related CMC domains.

Schedule Consultation
Top of Page